Aperture Bio, Inc.
Cambridge, MA
- UEI
- TJ1ZXK2DAVV3
- CAGE
- 9MYU5
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 34 Cambridge Terrace #3, Cambridge, MA 02140, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Cyclic immunofluorescent imaging in live cells - project summary/abstract cancer is a heterogeneous and dynamic… | National Cancer Institute | $809,988 | |
| Rapid, single cell proteomic profiling for biomarker development in precision oncology - project abstract nearly two… | National Cancer Institute | $942,272 | |
| Rapid, single cell proteomic profiling for biomarker development in precision oncology - project abstract nearly two… | National Cancer Institute | $734,980 |
About Aperture Bio, Inc.
Aperture Bio, Inc. is a woman-owned small business located in Cambridge, Massachusetts, focused on developing advanced imaging and molecular analysis technologies for precision medicine applications. Registered in the System for Award Management (SAM.gov) with a current registration valid through June 18, 2026, the company specializes in creating innovative diagnostic and research platforms that enable sophisticated cellular analysis, particularly in oncology and cell therapy domains.
The company has secured multiple federal grant awards from the National Cancer Institute (NCI), totaling approximately $805,000, to develop and validate cutting-edge single-cell proteomic profiling technologies. These grants specifically support the development of a cyclic immunofluorescent imaging platform designed to improve precision medicine approaches by enabling dynamic measurement of complex cellular functions and biological processes in live cells. The first grant, awarded on March 1, 2025, for $404,994, focuses on developing and assessing the feasibility of their imaging platform for preclinical applications in drug development, cell therapy manufacturing, regenerative medicine, and oncology research. A subsequent grant, awarded on May 20, 2024, aims to commercialize a platform for rapid molecular analysis of minute and fragile cell populations, with the goal of generating precise protein expression, cell state, and co-localization data. These projects address significant clinical challenges, such as understanding treatment resistance in cancer and developing more accurate diagnostic tools for selecting optimal therapeutic interventions.
Quick answers
What is Aperture Bio, Inc.'s UEI?
Aperture Bio, Inc.'s Unique Entity ID (UEI) in SAM.gov is TJ1ZXK2DAVV3.
What is Aperture Bio, Inc.'s CAGE code?
Aperture Bio, Inc.'s CAGE code is 9MYU5.
What is Aperture Bio, Inc.'s primary NAICS code?
Aperture Bio, Inc.'s primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Where is Aperture Bio, Inc. located?
Aperture Bio, Inc.'s physical address in SAM.gov is 34 Cambridge Terrace #3, Cambridge, MA 02140, USA.
Is Aperture Bio, Inc. registered in SAM.gov?
Yes. Aperture Bio, Inc.'s SAM.gov registration is active through May 12, 2027.
What is Aperture Bio, Inc.'s most recent federal award?
Aperture Bio, Inc.'s most recent federal grant award is Cyclic immunofluorescent imaging in live cells - project summary/abstract cancer is a heterogeneous and dynamic… (R43CA298597), from National Cancer Institute, on March 1, 2025.
On GovTribe
See Aperture Bio, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors